{"id":390033,"date":"2021-05-05T00:00:00","date_gmt":"2021-05-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0010-2021-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-us-eu-2021\/"},"modified":"2026-04-17T11:34:11","modified_gmt":"2026-04-17T11:34:11","slug":"unneon0010-2021-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-us-eu-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0010-2021-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-unmet-need-us-eu-2021\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck | Unmet Need | US\/EU | 2021"},"content":{"rendered":"<p>For the past decade, Erbitux-based regimens have been the mainstay of treatment for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN), but the launches of Merck &#038; Co.\u2019s Keytruda and Bristol Myers Squibb\u2019s Opdivo\u00a0are\u00a0transforming the SCCHN treatment algorithm. However, despite the label expansions of these immune checkpoint inhibitors to include recurrent or metastatic non-nasopharyngeal SCCHN, more-efficacious first-line treatment options are needed to address the unmet needs pertaining to this subpopulation of SCCHN.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals in medical oncologists\u2019 prescribing decisions for non-nasopharyngeal SCCHN?<\/li>\n<li>What are the hidden opportunities that developers could leverage?<\/li>\n<li>How do current therapies for non-nasopharyngeal SCCHN, such as Keytruda and Opdivo, perform on key clinical attributes for this patient population?<\/li>\n<li>What are the greatest unmet needs and most attractive opportunities in the treatment of non-nasopharyngeal SCCHN?<\/li>\n<li>What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles for non-nasopharyngeal SCCHN?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30\u00a0European medical oncologists fielded in February 2021<\/p>\n<p><strong>Key companies: <\/strong>Merck &#038; Co., Bristol Myers Squibb, Eli Lilly<\/p>\n<p><strong>Key drugs: <\/strong>Erbitux, Keytruda, Opdivo<\/p>\n","protected":false},"template":"","class_list":["post-390033","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390033\/revisions"}],"predecessor-version":[{"id":576411,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390033\/revisions\/576411"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}